Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-17
    E.g., 2018-10-17

Archive Search

7 results
6:00 PM, May 22, 2015  |  BC Extra | Top Story

Amgen exits brodalumab collaboration with AZ

brodalumab. AZ will hold rights to brodalumab in all territories excluding certain Asian territories where Kyowa Hakko Kirin
7:14 PM, Sep 08, 2014  |  BC Extra | Top Story

Benralizumab continuing despite Phase IIa COPD miss

eosinophil concentrations. AZ has worldwide rights, excluding Japan and certain Asian countries, to benralizumab from Kyowa Hakko Kirin
5:39 PM, Apr 30, 2013  |  BC Extra | Top Story

Aveo plunges on tivozanib briefing docs

has exclusive ex-Asian rights to the inhibitor of VEGF receptors 1, 2 and 3 from Kyowa Hakko Kirin
5:17 PM, Jan 17, 2013  |  BC Extra | Top Story

Public biotechs raise close to $1B

co-development and commercialization rights outside of Asia. Aveo has exclusive ex-Asian rights to tivozanib from Kyowa Hakko Kirin
4:18 PM, Jan 11, 2013  |  BC Extra | Top Story

ArQule's tivantinib misses in colorectal cancer

proceed with further development of tivantinib in colorectal cancer. Last year, ArQule and Asian partner Kyowa Hakko Kirin
5:27 PM, Oct 02, 2012  |  BC Extra | Top Story

ArQule slides on trial discontinuation

a Phase III trial in HCC by year end or early 2013. In August, partner Kyowa Hakko Kirin
5:31 PM, Dec 29, 2011  |  BC Extra | Top Story

FDA unveils REMS for fentanyl drugs

Onsolis from BioDelivery Sciences International Inc. (NASDAQ:BDSI) and Meda AB (SSE:MEDAA). ProStrakan is part of Kyowa Hakko Kirin